* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Solid Tumor
Survey
Document related concepts
Promoter (genetics) wikipedia , lookup
Gene regulatory network wikipedia , lookup
Eukaryotic transcription wikipedia , lookup
Epitranscriptome wikipedia , lookup
RNA polymerase II holoenzyme wikipedia , lookup
Silencer (genetics) wikipedia , lookup
RNA silencing wikipedia , lookup
Gene expression wikipedia , lookup
Transcriptional regulation wikipedia , lookup
Mitogen-activated protein kinase wikipedia , lookup
Non-coding RNA wikipedia , lookup
Paracrine signalling wikipedia , lookup
Transcript
Solid Tumor Archer™ FusionPlex™ Solid Tumor Panel Carcinoma Incidence and Mortality The Archer FusionPlex Solid Tumor Panel is a targeted sequencing assay that simultaneously detects and identifies fusions and other mutations in over 50 genes linked to carcinomas and other solid tumors. Life-threatening carcinomas make up over 80% of all cancers(1). In the United States, prostate cancer has the highest incidence rate, followed closely by female breast cancer, and lung cancer has by far the highest mortality rate. The power of the FusionPlex Solid Tumor panel lies in proprietary Anchored Multiplex PCR (AMP)™-based enrichment. This chemistry enables detection of all fusions associated with the genes in this panel in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints. Leading Cancer Rates by Site (1) Male and Female, United States (per 100,000 persons) 150 100 50 0 50 Lung and Bronchus Prostate Female Breast Non-Hodgkin Lymphoma Colon and Rectum Urinary Bladder Incidence Rate • Comprehensive – identify carcinoma-related fusions in a single assay • Detailed – characterize fusion partners at single-nucleotide resolution • Streamlined – reduce turn-around time and eliminate reflex testing • Flexible – works with all clinical sample types, including FFPE; only 20ng RNA input required For Research Use Only. Not for use in diagnostic procedures. Learn more about the Solid Tumor Panel at www.archerdx.com/solid-tumor Mortality Rate Assay Targets The panel includes specific breakpoints of the following genes. AKT3 EWSR1 NOTCH1/2 RAF1 ALK FGFR1/2/3 NRG1 RELA ARHGAP26 FGR NTRK1/2/3 RET AXL INSR NUMBL ROS1 BRAF MAML2 NUTM1 RSPO2/3 BRD3/4 MAST1/2 PDGFRA/B TERT EGFR MET PIK3CA TFE3 ERG MSMB PKN1 TFEB ESR1 MUSK PPARG THADA ETV1/4/5/6 MYB PRKCA/B TMPRSS2 (1) Visit archerdx.com/solid-tumor for references Receptor-mediated growth, proliferation and survival pathways Gene targets in the FusionPlex Solid Tumor Panel are shaded Receptor tyrosine kinases ALK EGFR FGR MET NTRK 1,2,3 PDGFRB ROS1 NRG1 NRG1 Ca2+ AXL FGFR 1,2,3 INSR MuSK PDGFRA RET Notch receptors NOTCH1 NOTCH2 Wnt Frizzled receptor PDK2 PDK1 GRB2 SHC PLC SOS PIP2 Ca2+ AKT p85 DAG β-catenin PI3KCA PTEN Apoptosis RAS-activated kinases BRAF RAF1 AKT3 PI3K p110 RAS PIP3 Protein kinase C (PKC) PRKCA PRKCB R-spondins RSPO2 RSPO3 Notch ICD •proliferation •cell survivial Protein synthesis Transcription factors/ RNA metabolism MAP kinase cascade: •cell proliferation •survival •differentation BRD3 ESR1 MAML2 PPARG TFEB Assay targets for oncogenic fusion detection include: • Receptor tyrosine kinases and ligand • MAP kinases • Tumor suppressors • Wnt signaling effectors • Transcription factors BRD4 ETV1,4,5,6 MYB RELA ERG EWSR1 NUT TFE3 c-MYC PTEN Visualize Fusion Detection with Single Nucleotide Resolution The FusionPlex Solid Tumor Panel in conjunction Archer Analysis software is optimized to detect both known and novel fusions. Superior Performance The FusionPlex Solid Tumor Panel demonstrates superior on-target and uniformity metrics using clinically relevant samples. FGFR2-PCM1 fusion annotations Read depth FusionPlex Solid Tumor performance metrics by input type 100 80 60 % on-target 40 % coverage uniformity* 20 0 Individual reads Adrenal gDNA Lung RNA Thyroid RNA Colon RNA FFPE Lung Tumor RNA *coverage uniformity ≥ 0.2x of the median Sequencing pileup of reads across FGFR2 exon 17 into the PCM1 gene, indicating an FGFR2-PCM1 fusion archerdx.com PN-MKT-0029 REV A